Answers are grounded in this paper and cite their sources.
Carcinoembryonic antigen (CEA) is widely used as a tumour biomarker in human medicine, but its applicability in dogs with pulmonary neoplasms remains poorly defined. This retrospective study evaluated serum CEA concentrations in dogs with primary and metastatic pulmonary neoplasms. Thirty-seven dogs with stored serum available were allocated to four groups: G1, primary pulmonary neoplasms treated by lobectomy; G2, primary pulmonary neoplasms not treated surgically; G3, pulmonary metastases from mammary neoplasms; and G4, pulmonary metastases from other extrathoracic neoplasms. CEA was measured by ELISA at diagnosis (D0) and 30 days after the start of treatment (D30). Concentrations differed among groups at D0 (p = 0.023) and D30 (p = 0.004), being highest in G3. Receiver operating characteristic analysis yielded areas under the curve of 0.798 at D0 (cut-off ≥ 0.90 ng/mL; sensitivity, 69.2%; specificity, 83.3%) and 0.938 at D30 (cut-off ≥ 1.05 ng/mL; sensitivity, 90.9%; specificity, 100%). Higher CEA was associated with an increased risk of death when all dogs were analysed together. CEA shows potential as a complementary biomarker for identifying dogs with pulmonary metastases of mammary origin, whereas its value for early monitoring of therapeutic response and as an independent prognostic marker was limited.
No takes yet. Share an insight, caveat, or question.
Cabral et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: